Molecular Excipient

105.0 -1.6 3 3 84.0 2 0.67
Present in 102 ZINC catalogs

Known Active Genes

There has not been any activity reported at 10μM or less for this excipient (per ChEBML)

Clinical Trials

This compound has been an intervention in the following clincial trials (per
Code Date Title Phase Status
NCT00215917 D-Serine Monotherapy for Schizophrenia Phase 1/Phase 2 Recruiting
NCT02156908 2014-08-01 D-serine and Cognitive Remediation in Schizophrenia Phase 2 Active, Not Recruiting
NCT01715051 2014-02-01 D-Serine for Cocaine Dependence Pilot Phase 2 Withdrawn
NCT01733407 2013-09-01 L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1 Phase 1/Phase 2 Active, Not Recruiting
NCT01835782 2013-01-01 Determining the Safety of L-serine in ALS Phase 1/Phase 2 Recruiting
NCT01804920 2013-01-01 D-Serine Treatment For Tardive Dyskinesia Phase 2/Phase 3 Recruiting
NCT01474395 2012-03-01 N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia Phase 2 Recruiting
NCT01459029 2011-11-01 High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia Phase 2 Not Yet Recruiting
NCT01128244 2010-04-01 Vitamin B6 Effects for Women Taking Birth Control Pills Phase 2/Phase 3 Completed
NCT01018056 2009-11-01 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission Phase 4 Completed
NCT00817336 2009-06-01 Biomarkers in Schizophrenia Phase 2 Completed
NCT00826202 2009-03-01 D-serine for the Schizophrenia Prodrome Phase 2 Active, Not Recruiting
NCT00816894 2009-01-01 D-serine Monotherapy for Schizophrenia Phase 2 Completed
NCT00499265 2007-04-01 Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery Phase 2 Completed
NCT00322023 2006-03-01 Safety and Effectiveness of D-Serine in Schizophrenia Phase 2 Active, Not Recruiting
NCT00243308 2005-10-01 Serp-1 for the Treatment of Acute Coronary Syndrome Phase 2 Terminated
NCT00237848 2005-02-01 D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia Phase 3 Completed
NCT00491569 2005-01-01 Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia Phase 2 Completed
NCT00138775 2004-10-01 Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia Phase 2 Recruiting
NCT00215904 2003-08-01 D-serine Adjuvant Treatment for Parkinson's Disease Phase 4 Completed
NCT00215878 2003-08-01 D-serine for Posttraumatic Stress Disorder Treatment Phase 2 Completed
NCT00237809 2002-09-01 D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia Phase 3 Recruiting

(Browse) Purchasable Analogs in ZINC

Functions of Serine

Ds - Dietary supplement


Route Formulation Per Unit Dose
Iv(infusion) Injection 50%
Iv(infusion) Solution, Injection 0.18%

More Information

Usage Over Time